JPWO2021054867A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021054867A5 JPWO2021054867A5 JP2022518285A JP2022518285A JPWO2021054867A5 JP WO2021054867 A5 JPWO2021054867 A5 JP WO2021054867A5 JP 2022518285 A JP2022518285 A JP 2022518285A JP 2022518285 A JP2022518285 A JP 2022518285A JP WO2021054867 A5 JPWO2021054867 A5 JP WO2021054867A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- immunocytokine
- amino acid
- chain constant
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940127130 immunocytokine Drugs 0.000 claims description 124
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 80
- 102000003812 Interleukin-15 Human genes 0.000 claims description 51
- 239000000178 monomer Substances 0.000 claims description 35
- 206010009944 Colon cancer Diseases 0.000 claims description 25
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 25
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 23
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 23
- 230000002519 immonomodulatory effect Effects 0.000 claims description 18
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 15
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 14
- 230000001613 neoplastic effect Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 10
- 206010005003 Bladder cancer Diseases 0.000 claims description 10
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 10
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 10
- 208000005017 glioblastoma Diseases 0.000 claims description 10
- 208000032839 leukemia Diseases 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 10
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 10
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 8
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 7
- 230000004071 biological effect Effects 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 230000037361 pathway Effects 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 206010000830 Acute leukaemia Diseases 0.000 claims description 5
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 5
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 5
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 208000017604 Hodgkin disease Diseases 0.000 claims description 5
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 claims description 5
- 208000032818 Microsatellite Instability Diseases 0.000 claims description 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 5
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 201000003444 follicular lymphoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 5
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 230000007547 defect Effects 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 claims description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000005734 heterodimerization reaction Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 238000010166 immunofluorescence Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 1
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025118407A JP2025182218A (ja) | 2019-09-19 | 2025-07-14 | Ｉｌ－１５／ｉｌ－１５ｒａに基づくヘテロ二量体タンパク質複合体を含む、イムノサイトカイン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2019129569A RU2753282C2 (ru) | 2019-09-19 | 2019-09-19 | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
| RU2019129569 | 2019-09-19 | ||
| PCT/RU2020/050233 WO2021054867A1 (ru) | 2019-09-19 | 2020-09-20 | Иммуноцитокин, включающий гетеро димерный белковый комплекс на основе il-15 и il-15rα |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025118407A Division JP2025182218A (ja) | 2019-09-19 | 2025-07-14 | Ｉｌ－１５／ｉｌ－１５ｒａに基づくヘテロ二量体タンパク質複合体を含む、イムノサイトカイン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022549276A JP2022549276A (ja) | 2022-11-24 |
| JP2022549276A5 JP2022549276A5 (https=) | 2023-09-28 |
| JPWO2021054867A5 true JPWO2021054867A5 (https=) | 2023-09-28 |
Family
ID=74873995
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518285A Pending JP2022549276A (ja) | 2019-09-19 | 2020-09-20 | Ｉｌ－１５／ｉｌ－１５ｒａに基づくヘテロ二量体タンパク質複合体を含む、イムノサイトカイン |
| JP2025118407A Pending JP2025182218A (ja) | 2019-09-19 | 2025-07-14 | Ｉｌ－１５／ｉｌ－１５ｒａに基づくヘテロ二量体タンパク質複合体を含む、イムノサイトカイン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025118407A Pending JP2025182218A (ja) | 2019-09-19 | 2025-07-14 | Ｉｌ－１５／ｉｌ－１５ｒａに基づくヘテロ二量体タンパク質複合体を含む、イムノサイトカイン |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230011234A1 (https=) |
| EP (1) | EP4032539A4 (https=) |
| JP (2) | JP2022549276A (https=) |
| KR (1) | KR20220145323A (https=) |
| CN (1) | CN115297885A (https=) |
| AR (1) | AR120011A1 (https=) |
| AU (1) | AU2020351560A1 (https=) |
| BR (1) | BR112022005173A2 (https=) |
| CA (1) | CA3151780A1 (https=) |
| CO (1) | CO2022003156A2 (https=) |
| JO (1) | JOP20220071A1 (https=) |
| MA (1) | MA56286B1 (https=) |
| MX (1) | MX2022003306A (https=) |
| PE (1) | PE20220603A1 (https=) |
| PH (1) | PH12022550688A1 (https=) |
| PY (1) | PY2056649A (https=) |
| RU (1) | RU2753282C2 (https=) |
| TW (1) | TWI891660B (https=) |
| UY (1) | UY38889A (https=) |
| WO (1) | WO2021054867A1 (https=) |
| ZA (1) | ZA202203254B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120463822A (zh) | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| CN116178572B (zh) * | 2022-02-28 | 2025-12-23 | 厦门柏慈生物科技有限公司 | 构建嵌合蛋白的嵌合区域、构建方法、嵌合蛋白及其应用 |
| CN115141283A (zh) * | 2022-03-10 | 2022-10-04 | 厦门柏慈生物科技有限公司 | 一种融合蛋白、制备方法及其应用 |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| CN116854821A (zh) * | 2022-08-15 | 2023-10-10 | 海徕科(北京)生物技术有限公司 | IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途 |
| CN121241063A (zh) * | 2023-08-04 | 2025-12-30 | 上海艾乐晞生物科技有限公司 | Sushi结构域突变体、融合蛋白、药物组合物和用途 |
| WO2025140627A1 (zh) * | 2023-12-28 | 2025-07-03 | 南通壹宸生物医药科技有限公司 | 融合抗体及其应用 |
| WO2026037415A1 (zh) * | 2024-08-16 | 2026-02-19 | 北京清辉联诺生物科技有限责任公司 | 一种IL15/IL15Rα复合物及其在细胞疗法领域的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| AU584417B2 (en) | 1985-04-01 | 1989-05-25 | Lonza Group Ag | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ES2221065T3 (es) * | 1996-08-16 | 2004-12-16 | The President And Fellows Of Harvard College | Proteinas de fusion de clase ii del mhc, solubles, monovalentes o polivalentes, y sus usos. |
| NZ506071A (en) * | 1998-02-19 | 2003-05-30 | Harvard College | Monovalent, multivalent, and multimeric major histocompatibility complex (MHC) binding domain fusion proteins and conjugates, and uses therefore |
| WO2001046261A1 (en) * | 1999-12-23 | 2001-06-28 | Zymogenetics, Inc. | Method for treating inflammation |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| DK2160401T3 (da) * | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
| CN107880136B (zh) * | 2010-09-21 | 2021-11-12 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| RU2687043C2 (ru) * | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| BR112016002614B8 (pt) | 2013-08-08 | 2023-11-07 | Hopitaux Paris Assist Publique | Imunocitoquina e composição farmacêutica |
| RU2689717C2 (ru) * | 2014-01-08 | 2019-05-28 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Гетеродимерный белок il-15 и его применения |
| CA3151221C (en) * | 2014-06-30 | 2026-01-13 | Altor Bioscience Corporation | Il-15-based molecules and methods of use thereof |
| AU2015366795B2 (en) | 2014-12-19 | 2020-12-17 | Jiangsu Hengrui Medicine Co., Ltd. | Interleukin 15 protein complex and use thereof |
| RU2656181C1 (ru) * | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
| CN110214147A (zh) * | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | IL15/IL15Rα异源二聚体FC-融合蛋白 |
| CN118562016A (zh) * | 2016-10-21 | 2024-08-30 | 艾尔特生物科技公司 | 基于多聚体il-15的分子 |
| CN117986384A (zh) * | 2017-03-06 | 2024-05-07 | 艾尔特生物科技公司 | 与il-12和il-18的基于il-15的融合物 |
| RU2665790C1 (ru) | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
| US11084863B2 (en) * | 2017-06-30 | 2021-08-10 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains |
| US20210017247A1 (en) * | 2017-07-03 | 2021-01-21 | Torque Therapeutics, Inc. | Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof |
-
2019
- 2019-09-19 RU RU2019129569A patent/RU2753282C2/ru active
-
2020
- 2020-09-18 AR ARP200102607A patent/AR120011A1/es unknown
- 2020-09-20 MA MA56286A patent/MA56286B1/fr unknown
- 2020-09-20 WO PCT/RU2020/050233 patent/WO2021054867A1/ru not_active Ceased
- 2020-09-20 CA CA3151780A patent/CA3151780A1/en active Pending
- 2020-09-20 EP EP20865705.6A patent/EP4032539A4/en active Pending
- 2020-09-20 KR KR1020227013100A patent/KR20220145323A/ko active Pending
- 2020-09-20 JP JP2022518285A patent/JP2022549276A/ja active Pending
- 2020-09-20 PE PE2022000447A patent/PE20220603A1/es unknown
- 2020-09-20 US US17/761,838 patent/US20230011234A1/en active Pending
- 2020-09-20 BR BR112022005173A patent/BR112022005173A2/pt unknown
- 2020-09-20 MX MX2022003306A patent/MX2022003306A/es unknown
- 2020-09-20 PH PH1/2022/550688A patent/PH12022550688A1/en unknown
- 2020-09-20 CN CN202080080165.8A patent/CN115297885A/zh active Pending
- 2020-09-20 AU AU2020351560A patent/AU2020351560A1/en active Pending
- 2020-09-21 TW TW109132634A patent/TWI891660B/zh active
- 2020-09-21 PY PY202002056649A patent/PY2056649A/es unknown
- 2020-09-22 UY UY0001038889A patent/UY38889A/es unknown
-
2022
- 2022-03-17 JO JOP/2022/0071A patent/JOP20220071A1/ar unknown
- 2022-03-18 ZA ZA2022/03254A patent/ZA202203254B/en unknown
- 2022-03-18 CO CONC2022/0003156A patent/CO2022003156A2/es unknown
-
2025
- 2025-07-14 JP JP2025118407A patent/JP2025182218A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7774025B2 (ja) | 抗体－サイトカイングラフト化タンパク質及び癌の治療における使用方法 | |
| JP7464764B2 (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| RU2019129569A (ru) | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ | |
| CN107922503B (zh) | 一种pdl-1抗体、其药物组合物及其用途 | |
| EP3227342B1 (en) | Proteinaceous heterodimer and use thereof | |
| JP2021525087A5 (https=) | ||
| CN105968206B (zh) | 抗erbb3抗体 | |
| JP2020520370A5 (https=) | ||
| RU2019134352A (ru) | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap | |
| IL263466B2 (en) | Anti-CD3 antibodies and methods of using them | |
| IL271260B1 (en) | Multispecific antibodies and methods for their preparation and use | |
| JPWO2021054867A5 (https=) | ||
| WO2021238904A1 (zh) | Fc-CD80融合蛋白和其缀合物以及它们的用途 | |
| TW202108629A (zh) | 用於t細胞活化之抗體 | |
| CN112969718A (zh) | Il-15蛋白复合物联合pd-l1抗体用于治疗肿瘤疾病的用途 | |
| JPWO2020172605A5 (https=) | ||
| JPWO2021222578A5 (https=) | ||
| TW202104263A (zh) | 雙特異性CD123xCD3雙抗體在血液系統惡性腫瘤治療中的給藥方案 | |
| WO2015054958A1 (zh) | 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途 | |
| US6007807A (en) | Induction of tumour immunity by injection of hybrid cells | |
| JPH05506037A (ja) | インターロイキン２レセプターに対するモノクローナル抗体 | |
| CN113039207B (zh) | 人源化抗人pd-l1单克隆抗体及其制备方法和用途 | |
| JPWO2020218951A5 (https=) | ||
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
| JPWO2022101458A5 (https=) |